[go: up one dir, main page]

ES2165768A1 - Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2165768A1
ES2165768A1 ES009901580A ES9901580A ES2165768A1 ES 2165768 A1 ES2165768 A1 ES 2165768A1 ES 009901580 A ES009901580 A ES 009901580A ES 9901580 A ES9901580 A ES 9901580A ES 2165768 A1 ES2165768 A1 ES 2165768A1
Authority
ES
Spain
Prior art keywords
group
straight
lower alkyl
branched lower
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009901580A
Other languages
English (en)
Other versions
ES2165768B1 (es
Inventor
Forner Dolors Fernandez
Quinones Maria Prat
Albero Maria Antonia Buil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8309225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2165768(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to ES009901580A priority Critical patent/ES2165768B1/es
Priority to HK02103992A priority patent/HK1042487B/en
Priority to KR1020027000479A priority patent/KR100773844B1/ko
Priority to PCT/EP2000/006469 priority patent/WO2001004118A2/en
Priority to RU2002103605A priority patent/RU2264401C3/ru
Priority to TR2002/00768T priority patent/TR200200768T2/xx
Priority to SK43-2002A priority patent/SK287480B6/sk
Priority to CA2381165A priority patent/CA2381165C/en
Priority to BRPI0012434A priority patent/BRPI0012434B8/pt
Priority to EEP200200017A priority patent/EE04915B3/et
Priority to PT00951361T priority patent/PT1200431E/pt
Priority to CNB2006100068921A priority patent/CN100451018C/zh
Priority to DE60001840A priority patent/DE60001840D1/de
Priority to DK00951361.5T priority patent/DK1200431T6/en
Priority to UA2002010323A priority patent/UA73509C2/uk
Priority to AU64330/00A priority patent/AU779881C/en
Priority to HU0202100A priority patent/HU228594B1/hu
Priority to ES951361T priority patent/ES2193098T7/es
Priority to PL357160A priority patent/PL204024B1/pl
Priority to KR1020067027730A priority patent/KR100854315B1/ko
Priority to DE60001840.7T priority patent/DE60001840T4/de
Priority to EP00951361.5A priority patent/EP1200431B3/en
Priority to KR1020067027733A priority patent/KR100854321B1/ko
Priority to AT00951361T priority patent/ATE235492T1/de
Priority to IL14753300A priority patent/IL147533A0/xx
Priority to CNB008127549A priority patent/CN1272334C/zh
Priority to JP2001509727A priority patent/JP4030040B2/ja
Priority to CZ2002-121A priority patent/CZ304292B6/cs
Priority to SI200030108T priority patent/SI1200431T1/xx
Priority to PE2000000691A priority patent/PE20010397A1/es
Priority to MYPI20003178 priority patent/MY126959A/en
Priority to EG20000907A priority patent/EG24066A/xx
Priority to TW089113865A priority patent/TWI284644B/zh
Priority to CO00052873A priority patent/CO5200759A1/es
Priority to ARP000103613A priority patent/AR029760A1/es
Priority to UY26244A priority patent/UY26244A1/es
Priority to ZA200200232A priority patent/ZA200200232B/xx
Priority to NO20020180A priority patent/NO329484B3/no
Priority to US10/047,464 priority patent/US6750226B2/en
Priority to BG106301A priority patent/BG65565B1/bg
Publication of ES2165768A1 publication Critical patent/ES2165768A1/es
Application granted granted Critical
Publication of ES2165768B1 publication Critical patent/ES2165768B1/es
Priority to US10/740,264 priority patent/US7109210B2/en
Priority to US11/116,777 priority patent/US7078412B2/en
Priority to AU2005202144A priority patent/AU2005202144B2/en
Priority to RU2005121162/04A priority patent/RU2306312C2/ru
Priority to JP2005203365A priority patent/JP4951217B2/ja
Priority to US11/325,059 priority patent/US7196098B2/en
Priority to US11/324,919 priority patent/US7214687B2/en
Priority to US11/636,181 priority patent/US7358260B2/en
Priority to US12/074,929 priority patent/US7750023B2/en
Priority to US12/787,772 priority patent/US7897617B2/en
Priority to US13/011,131 priority patent/US8129405B2/en
Priority to UY0001033494A priority patent/UY33494A/es
Priority to US13/354,873 priority patent/US8513279B2/en
Priority to BE2013C001C priority patent/BE2013C001I2/fr
Priority to CY2013001C priority patent/CY2013001I1/el
Priority to FR13C0001C priority patent/FR13C0001I2/fr
Priority to LU92132C priority patent/LU92132I2/fr
Priority to NO2013002C priority patent/NO2013002I2/no
Priority to US13/939,742 priority patent/US8802699B2/en
Priority to US14/311,102 priority patent/US9056100B2/en
Priority to US14/712,866 priority patent/US9333195B2/en
Priority to US15/019,009 priority patent/USRE46417E1/en
Priority to US15/095,036 priority patent/US9687478B2/en
Priority to US15/599,646 priority patent/US10034867B2/en
Priority to US16/045,333 priority patent/US10588895B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nuevos derivados de quinuclidina y composiciones farmacéuticas que los contienen, teniendo dichos derivados de quinuclidina la fórmula (I): **FIGURA** en donde: C es un fenilo, un compuesto heteroaromático de 4 a 9 átomos de carbono conteniendo uno o más heteroátomos, o un grupo naftalenilo, 5,6,7,8- tetrahidronaftalenllo o bifenilo; R{sup,1}, R{sup,2} y R{sup,3} cada uno independientemente representan un átomo de hidrógeno o halógeno, o un grupo hidroxilo -CN, -NO{sub,2}, o un grupo orgánico. n es un número del 0 al 4; A representa un grupo - CH{sub,2}-, -CH=CR{sup,6}, CR{sup, 6}=CH, CR{sup,6}R{sup, 7}-, -CO-, -O-, -S-, -S(O)-, SO{sub,2} o -NR-{sup, 6}-, en donde R{sup,6} y R{sup,7} cada uno independientemente representan un átomo de hidrógeno, o un grupo orgánico; m es un número del 0 al 8; a condición de que cuando m = 0, A no es -CH{sub,2}-; p es un número del 1 al 2 y la sustitución en el anillo azoniabicíclico puede estar en la posición 2,3 o 4 incluyendo todas las posibilidades de configuraciones de los carbonos asimétricos, B representa un grupo orgánico bicíclico o tricíclico, homocíclico o heterocíclico; y X representa un anión farmacéuticamente aceptable de un ácido mono o polivalente.
ES009901580A 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. Expired - Fee Related ES2165768B1 (es)

Priority Applications (65)

Application Number Priority Date Filing Date Title
ES009901580A ES2165768B1 (es) 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
HK02103992A HK1042487B (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
KR1020027000479A KR100773844B1 (ko) 1999-07-14 2000-07-07 신규한 퀴누클리딘 유도체 및 그것의 무스카린 엠3 수용체리간드로의 이용
PCT/EP2000/006469 WO2001004118A2 (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
RU2002103605A RU2264401C3 (ru) 1999-07-14 2000-07-07 Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения и промежуточные вещества
TR2002/00768T TR200200768T2 (tr) 1999-07-14 2000-07-07 Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri
SK43-2002A SK287480B6 (sk) 1999-07-14 2000-07-07 Chinuklidínové deriváty, spôsob ich prípravy, liečivé kompozície, ktoré ich obsahujú, a ich použitie
CA2381165A CA2381165C (en) 1999-07-14 2000-07-07 Novel quinuclidine derivatives and medicinal compositions containing the same
BRPI0012434A BRPI0012434B8 (pt) 1999-07-14 2000-07-07 compostos ésteres de quinuclidina úteis como antagonistas de receptores m3 muscarínicos
EEP200200017A EE04915B3 (et) 1999-07-14 2000-07-07 Kinuklidiinderivaadid, nende valmistamismeetod, vaheühendid, farmatseutiline kompositsioon ja nende kasutamine
PT00951361T PT1200431E (pt) 1999-07-14 2000-07-07 Derivados de quinuclidina e sua utilizacao como ligandos de receptores muscarinicos m3
CNB2006100068921A CN100451018C (zh) 1999-07-14 2000-07-07 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途
DE60001840A DE60001840D1 (de) 1999-07-14 2000-07-07 Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
DK00951361.5T DK1200431T6 (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
UA2002010323A UA73509C2 (uk) 1999-07-14 2000-07-07 Хінуклідинові похідні та їх використання як лігандів мускаринового м3-рецептора
AU64330/00A AU779881C (en) 1999-07-14 2000-07-07 Quinuclidine derivates and their use as muscarinic M3 receptor ligands
HU0202100A HU228594B1 (en) 1999-07-14 2000-07-07 Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same
ES951361T ES2193098T7 (es) 1999-07-14 2000-07-07 Derivados de quinuclidina y su uso como ligandos de los receptores muscarínicos M3
PL357160A PL204024B1 (pl) 1999-07-14 2000-07-07 Nowe pochodne chinuklidyny, sposób ich wytwarzania, zastosowanie i zawierające je kompozycje farmaceutyczne
KR1020067027730A KR100854315B1 (ko) 1999-07-14 2000-07-07 신규한 퀴누클리딘 유도체 및 그것의 무스카린 엠3 수용체리간드로의 이용
DE60001840.7T DE60001840T4 (de) 1999-07-14 2000-07-07 Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
EP00951361.5A EP1200431B3 (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
KR1020067027733A KR100854321B1 (ko) 1999-07-14 2000-07-07 신규한 퀴누클리딘 유도체 및 그것의 무스카린 엠3 수용체리간드로의 이용
AT00951361T ATE235492T1 (de) 1999-07-14 2000-07-07 Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
IL14753300A IL147533A0 (en) 1999-07-14 2000-07-07 Novel quinuclidine derivatives and medicinal compositions containing the same
CNB008127549A CN1272334C (zh) 1999-07-14 2000-07-07 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途
JP2001509727A JP4030040B2 (ja) 1999-07-14 2000-07-07 キヌクリジン誘導体およびそれらのムスカリンｍ３レセプターリガンドとしての使用
CZ2002-121A CZ304292B6 (cs) 1999-07-14 2000-07-07 Chinuklidinové deriváty, způsob jejich přípravy a použití a farmaceutická kompozice s jejich obsahem
SI200030108T SI1200431T1 (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
PE2000000691A PE20010397A1 (es) 1999-07-14 2000-07-11 Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 y composiciones farmaceuticas que los contienen
MYPI20003178 MY126959A (en) 1999-07-14 2000-07-12 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
EG20000907A EG24066A (en) 1999-07-14 2000-07-12 Novel quinuclidine derivatives and medicinal compositions containing the same
TW089113865A TWI284644B (en) 1999-07-14 2000-07-12 Novel quinuclidine derivatives and medicinal compositions containing the same
CO00052873A CO5200759A1 (es) 1999-07-14 2000-07-13 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen
ARP000103613A AR029760A1 (es) 1999-07-14 2000-07-13 Derivados de quinuclidina, proceso para preparar dichos derivados, compuestos intermediarios utilizables en dicho proceso, composiciones farmaceuticas formuladas con dichos derivados y uso de dichos derivados para la produccion de medicamentos para el tratamiento de enfermedades respiratorias, urina
UY26244A UY26244A1 (es) 1999-07-14 2000-07-14 Nuevos derivados de quinuclidina y composiciones farmacéuticas que los contienen.
ZA200200232A ZA200200232B (en) 1999-07-14 2002-01-10 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands.
NO20020180A NO329484B3 (no) 1999-07-14 2002-01-14 Nye kinuklidinderivater og medisinske sammensetninger inneholdende det samme, samt anvendelse derav for fremstilling av medikamenter
US10/047,464 US6750226B2 (en) 1999-07-14 2002-01-14 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
BG106301A BG65565B1 (bg) 1999-07-14 2002-01-14 Хинуклидинови производни и тяхното използване като мускаринови м3 рецепторни лиганди
US10/740,264 US7109210B2 (en) 1999-07-14 2003-12-17 Quinuclidine derivatives and medicinal compositions containing the same
US11/116,777 US7078412B2 (en) 1999-07-14 2005-04-28 Quinuclidine derivatives and medicinal compositions containing the same
AU2005202144A AU2005202144B2 (en) 1999-07-14 2005-05-18 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
RU2005121162/04A RU2306312C2 (ru) 1999-07-14 2005-07-06 Производные хинуклидина, фармацевтическая композиция и способ лечения респираторных заболеваний
JP2005203365A JP4951217B2 (ja) 1999-07-14 2005-07-12 キヌクリジン誘導体およびそれらのムスカリンｍ３レセプターリガンドとしての使用
US11/325,059 US7196098B2 (en) 1999-07-14 2006-01-03 Quinuclidine derivatives and medicinal compositions containing the same
US11/324,919 US7214687B2 (en) 1999-07-14 2006-01-03 Quinuclidine derivatives and medicinal compositions containing the same
US11/636,181 US7358260B2 (en) 1999-07-14 2006-12-08 Quinuclidine derivatives and medicinal compositions containing the same
US12/074,929 US7750023B2 (en) 1999-07-14 2008-03-07 Quinuclidine derivatives and medicinal compositions containing the same
US12/787,772 US7897617B2 (en) 1999-07-14 2010-05-26 Quinuclidine derivatives and medicinal compositions containing the same
US13/011,131 US8129405B2 (en) 1999-07-14 2011-01-21 Quinuclidine derivatives and medicinal compositions containing the same
UY0001033494A UY33494A (es) 1999-07-14 2011-07-08 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen
US13/354,873 US8513279B2 (en) 1999-07-14 2012-01-20 Quinuclidine derivatives and medicinal compositions containing the same
BE2013C001C BE2013C001I2 (es) 1999-07-14 2013-01-03
CY2013001C CY2013001I1 (el) 1999-07-14 2013-01-07 Nεα παραγωγα κινουκλιδινης και ιατρικα σκευασματα που τα πepιεχουν
FR13C0001C FR13C0001I2 (fr) 1999-07-14 2013-01-08 Derives de quinuclidine et leur utilisation comme ligands des recepteurs m3 muscariniques
LU92132C LU92132I2 (fr) 1999-07-14 2013-01-16 Sel d'aclidinium avec anion d'un acide mono ou polyvalent pharmaceutiquement acceptable particulièrement le bromure d'aclidinium
NO2013002C NO2013002I2 (no) 1999-07-14 2013-01-18 Aklidiniumsalt med et farmaøytisk akseptabelt anion av en mono-eller polyvalent syre, spesielt aklidiniumbromid
US13/939,742 US8802699B2 (en) 1999-07-14 2013-07-11 Quinuclidine derivatives and medicinal compositions containing the same
US14/311,102 US9056100B2 (en) 1999-07-14 2014-06-20 Quinuclidine derivatives and medicinal compositions containing the same
US14/712,866 US9333195B2 (en) 1999-07-14 2015-05-14 Quinuclidine derivatives and medicinal compositions containing the same
US15/019,009 USRE46417E1 (en) 1999-07-14 2016-02-09 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
US15/095,036 US9687478B2 (en) 1999-07-14 2016-04-09 Quinuclidine derivatives and medicinal compositions containing the same
US15/599,646 US10034867B2 (en) 1999-07-14 2017-05-19 Quinuclidine derivatives and medicinal compositions containing the same
US16/045,333 US10588895B2 (en) 1999-07-14 2018-07-25 Quinuclidine derivatives and medicinal compositions containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901580A ES2165768B1 (es) 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.

Publications (2)

Publication Number Publication Date
ES2165768A1 true ES2165768A1 (es) 2002-03-16
ES2165768B1 ES2165768B1 (es) 2003-04-01

Family

ID=8309225

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009901580A Expired - Fee Related ES2165768B1 (es) 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES951361T Active ES2193098T7 (es) 1999-07-14 2000-07-07 Derivados de quinuclidina y su uso como ligandos de los receptores muscarínicos M3

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES951361T Active ES2193098T7 (es) 1999-07-14 2000-07-07 Derivados de quinuclidina y su uso como ligandos de los receptores muscarínicos M3

Country Status (39)

Country Link
US (16) US6750226B2 (es)
EP (1) EP1200431B3 (es)
JP (2) JP4030040B2 (es)
KR (3) KR100854315B1 (es)
CN (2) CN100451018C (es)
AR (1) AR029760A1 (es)
AT (1) ATE235492T1 (es)
AU (1) AU2005202144B2 (es)
BE (1) BE2013C001I2 (es)
BG (1) BG65565B1 (es)
BR (1) BRPI0012434B8 (es)
CA (1) CA2381165C (es)
CO (1) CO5200759A1 (es)
CY (1) CY2013001I1 (es)
CZ (1) CZ304292B6 (es)
DE (2) DE60001840T4 (es)
DK (1) DK1200431T6 (es)
EE (1) EE04915B3 (es)
EG (1) EG24066A (es)
ES (2) ES2165768B1 (es)
FR (1) FR13C0001I2 (es)
HK (1) HK1042487B (es)
HU (1) HU228594B1 (es)
IL (1) IL147533A0 (es)
LU (1) LU92132I2 (es)
MY (1) MY126959A (es)
NO (2) NO329484B3 (es)
PE (1) PE20010397A1 (es)
PL (1) PL204024B1 (es)
PT (1) PT1200431E (es)
RU (2) RU2264401C3 (es)
SI (1) SI1200431T1 (es)
SK (1) SK287480B6 (es)
TR (1) TR200200768T2 (es)
TW (1) TWI284644B (es)
UA (1) UA73509C2 (es)
UY (2) UY26244A1 (es)
WO (1) WO2001004118A2 (es)
ZA (1) ZA200200232B (es)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2206021A1 (es) * 2002-04-16 2004-05-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2298049A1 (es) * 2006-07-21 2008-05-01 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation

Families Citing this family (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
PT1353919E (pt) * 2000-12-28 2006-11-30 Almirall Prodesfarma Ag Novos derivados de quinuclidina e composições medicinais contendo os mesmos
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CA2458534C (en) 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2003053966A2 (en) * 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
US7405224B2 (en) 2002-01-31 2008-07-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions
DE10203753A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
AU2002356369A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Xanthine derivatives as muscarinic receptor antagonists
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
WO2004106333A1 (en) 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
EP1644356A1 (en) 2003-07-11 2006-04-12 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
TW200519109A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
UY28417A1 (es) * 2003-07-17 2005-02-28 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
EP1651222A1 (en) * 2003-07-29 2006-05-03 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
KR20060052912A (ko) * 2003-07-29 2006-05-19 베링거 인겔하임 인터내셔날 게엠베하 항콜린제와 스테로이드의 배합물 및 흡입으로 호흡기장애를 치료하기 위한 이의 용도
BRPI0413129A (pt) * 2003-07-29 2006-10-03 Boehringer Ingelheim Int medicamentos para inalação compreendendo betamiméticos e anticolinérgico
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ATE526967T1 (de) * 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
PE20050963A1 (es) * 2003-10-14 2006-01-11 Glaxo Group Ltd Compuestos derivados de 8-azoniabiciclo [3.2.1]octanos como antagonistas de receptores de acetilcolina muscarinicos
AP2006003575A0 (en) * 2003-10-17 2006-04-30 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
PT1765404E (pt) * 2004-05-31 2009-03-31 Almirall Lab Combinações compreendendo agentes antimuscarínicos e agonistas beta-adrenérgicos
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
DE602004018844D1 (de) * 2004-06-16 2009-02-12 Ranbaxy Lab Ltd Als antagonisten des muscarinrezeptors geeignete xanthinderivate
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006072599A2 (en) 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
JP2008532973A (ja) * 2005-03-09 2008-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とｐｄｅ５−阻害剤に基づく新規な医薬組成物
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
CA2603433A1 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
WO2007016650A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2009503099A (ja) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1924553A1 (en) * 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
EP1937068A4 (en) * 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
EP1978955A1 (en) * 2006-01-06 2008-10-15 Boehringer Ingelheim International GmbH New pharmaceutical compositions based on anticholinergics and andolast
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AR060536A1 (es) 2006-04-20 2008-06-25 Glaxo Group Ltd Agonista del receptor de glucocorticoides y composiciones farmaceuticas
SI2013211T1 (sl) 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
JP2009543658A (ja) * 2006-07-14 2009-12-10 アストラゼネカ・アクチエボラーグ 乾燥粉末状の薬を投与するための吸入装置及び配送装置
AU2007275931B2 (en) 2006-07-19 2011-06-16 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0622827D0 (en) 2006-11-15 2006-12-27 Glaxo Group Ltd Sheet driver for use in a drug dispenser
EP2114972A2 (en) * 2006-12-13 2009-11-11 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of muscarinic receptor antagonists and beta-agonists for the treatment of copd and chronic bronchitis
PL2104535T3 (pl) 2007-01-10 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywujące kanały
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
HRP20110556T1 (hr) * 2007-02-21 2011-09-30 Almirall Novi postupci
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
BRPI0816219B8 (pt) 2007-09-07 2021-05-25 Theravance Biopharma R&D Ip Llc compostos contendo guanidina úteis como antagonistas de receptor muscarínico, composição farmacêutica e uso
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
EP2222637A1 (en) * 2007-12-14 2010-09-01 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
KR101605576B1 (ko) 2008-05-27 2016-03-22 아스트라제네카 아베 페녹시피리디닐아미드 유도체 및 ｐｄｅ４ 매개 질환 상태의 치료에서의 그의 용도
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
EP2154136A1 (en) * 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
MX344153B (es) 2009-04-09 2016-12-07 Novartis Ag Proceso para la preparación de sales de pirrolidinio.
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
UY32571A (es) 2009-04-24 2010-11-30 Glaxo Group Ltd Compuestos derivados de pirazol amida
TWI516487B (zh) 2009-04-30 2016-01-11 葛蘭素集團有限公司 新穎化合物、其醫藥組合物及作為激酶活性抑制劑之用途
EP2435025B1 (en) 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0910537D0 (en) 2009-06-18 2009-07-29 Ivax Pharmaceuticals Ireland Inhaler
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
KR101721280B1 (ko) 2009-08-17 2017-03-29 인텔리카인, 엘엘씨 헤테로사이클릭 화합물 및 이의 용도
IN2012DN01453A (es) 2009-08-20 2015-06-05 Novartis Ag
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
WO2012052458A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
CA2858581A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2666465A1 (en) * 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
KR20150092173A (ko) * 2012-12-05 2015-08-12 키에시 파르마슈티시 엣스. 피. 에이. Pde4-억제제로서 페닐에틸피리딘 유도체
SMT202200303T1 (it) 2012-12-17 2022-09-14 Almirall Sa Aclidinio per l’uso nell’aumento dell’attività fisica nella vita quotidiana in un paziente con broncopneumopatia cronica ostruttiva
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
AU2014292722B2 (en) * 2013-07-13 2017-03-09 Beijing Showby Pharmaceutical Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
WO2015042078A2 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CN103755698A (zh) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 一锅法制备阿地溴铵的工艺
CN103755699A (zh) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 一种2-羟基-2,2-二噻吩-2-基乙酸-1-氮杂二环[2,2,2]辛-3(r)-基酯制备方法
CZ2014188A3 (cs) 2014-03-26 2015-10-07 Zentiva, K.S. Nové formy aclidinium chloridu a způsob jejich přípravy
JP6517318B2 (ja) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
EA033571B1 (ru) 2014-04-24 2019-11-06 Novartis Ag Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
KR102570702B1 (ko) 2015-03-02 2023-08-24 가부시키가이샤 엘티티 바이오파마 퀴누클리딘 유도체
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
WO2016162878A1 (en) * 2015-04-04 2016-10-13 Harman Finochem Limited An advantageous process for preparing 1-azoniabicyclo[2.2.2]octane,3-[(hydroxydi-2-thienylacetyl)oxy]-1-(3¬phenoxypropyl)-, bromide, (3r)- and its novel crystalline form-i
CZ2015257A3 (cs) 2015-04-16 2016-10-26 Zentiva, K.S. Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu
CN105085355B (zh) * 2015-06-25 2017-11-14 御盛隆堂药业有限责任公司 一种取代的吡咯烷羧酸酯类化合物及其制备方法和应用
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
WO2018094392A1 (en) 2016-11-21 2018-05-24 Lupin Inc. Medicament dispenser
GB201700727D0 (en) 2017-01-16 2017-03-01 Teva Pharma Inhalers and airflow adaptors therefor
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190076607A1 (en) 2017-09-13 2019-03-14 Lupin Atlantis Holdings Sa Inhaler and mesh for an inhaler
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2019129801A1 (en) 2017-12-28 2019-07-04 Linnea S.A. Process for the purification of methyl-2,2-dithienylglycolate
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2020058823A1 (en) 2018-09-17 2020-03-26 Lupin, Inc. Dose indicator assembly for a medicament dispenser
MX2021015133A (es) 2019-06-10 2022-01-24 Novartis Ag Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
WO2021195353A1 (en) 2020-03-25 2021-09-30 Lupin Inc. Multi-carrier medicament dispensers
CN116194114A (zh) 2020-03-26 2023-05-30 葛兰素史密斯克莱知识产权发展有限公司 用于防止或治疗病毒感染的组织蛋白酶抑制剂
US20230270956A1 (en) 2020-07-23 2023-08-31 Lupin Inc. Dose counter assemblies for medicament dispensers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302699A2 (en) * 1987-08-03 1989-02-08 Walton S.A. Improvements relating to n-substituted benzamides
EP0424021A1 (en) * 1989-10-19 1991-04-24 Pfizer Limited Antimuscarinic bronchodilators

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091570A (en) 1960-08-08 1963-05-28 Lakeside Lab Inc Antidepressant: 3-pyrrolidyl glycolates
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
FR2539135B1 (fr) 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4843074A (en) 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
DK0500864T3 (da) 1990-09-06 2001-11-12 Pfizer Antimuskarine bronkodilatorer
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
EP0640354B1 (en) 1990-09-26 2001-12-05 Pharmachemie B.V. Whirl chamber powder inhaler
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5263480A (en) 1991-02-01 1993-11-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
GB9119705D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
ES2129117T3 (es) 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
PL173090B1 (pl) 1992-12-18 1998-01-30 Schering Corp Inhalator do sproszkowanych lekarstw
KR970701174A (ko) 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5569447A (en) * 1994-04-19 1996-10-29 The United States Of America Represented By The Secretary Department Of Health And Human Services Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives
EP0772656B1 (en) 1994-07-29 2001-03-21 Minnesota Mining And Manufacturing Company Acrylic syrup curable to a crosslinked viscoelastomeric material
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
MX9707864A (es) 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida por salmeterol.
DE69617431T2 (de) 1995-06-21 2002-08-01 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
ATE253896T1 (de) 1998-06-18 2003-11-15 Boehringer Ingelheim Pharma Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
DE19847968A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
SK10342002A3 (sk) 2000-01-31 2003-12-02 Pfizer Products Inc. Pyrimidínkarboxamidy užitočné ako selektívne inhibítory izozymov PDE4
US6924292B2 (en) 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
GB0008485D0 (en) 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
US6777132B2 (en) 2000-04-27 2004-08-17 Valence Technology, Inc. Alkali/transition metal halo—and hydroxy-phosphates and related electrode active materials
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
UA73986C2 (uk) 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
US6852728B2 (en) 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
EP1333830A2 (de) 2000-10-31 2003-08-13 Boehringer Ingelheim Pharma GmbH & Co.KG Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden
US6608054B2 (en) 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US6620438B2 (en) 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020151541A1 (en) 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020122773A1 (en) 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20020193392A1 (en) 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10056104A1 (de) 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20100310477A1 (en) 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
PT1353919E (pt) 2000-12-28 2006-11-30 Almirall Prodesfarma Ag Novos derivados de quinuclidina e composições medicinais contendo os mesmos
US20020179087A1 (en) 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US20020189610A1 (en) 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
DE10104367A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10104370A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Arzneimittelkompositionen mit geringeren Nebenwirkungen
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
MXPA03010162A (es) 2001-05-25 2004-03-10 Pfizer Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
JP2004530705A (ja) 2001-05-25 2004-10-07 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 閉塞性気道疾患及びその他の炎症性疾患を治療するためのｐｄｅ４インヒビター及びチオトロピウム又はその誘導体の組み合わせ
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
WO2003024452A1 (de) 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur inhalation
US6919325B2 (en) 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US6790856B2 (en) 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
PT3494995T (pt) 2002-03-01 2020-03-30 Chiesi Farm Spa Formulação superfina de formoterol
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7094788B2 (en) 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PL219032B1 (pl) 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
HRP20050572A2 (en) 2002-11-27 2006-08-31 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
CA2519682A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
US20060147382A1 (en) 2003-03-28 2006-07-06 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
US20050026886A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
EP1651222A1 (en) 2003-07-29 2006-05-03 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
BRPI0413129A (pt) 2003-07-29 2006-10-03 Boehringer Ingelheim Int medicamentos para inalação compreendendo betamiméticos e anticolinérgico
US20050026887A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
KR20060052912A (ko) 2003-07-29 2006-05-19 베링거 인겔하임 인터내셔날 게엠베하 항콜린제와 스테로이드의 배합물 및 흡입으로 호흡기장애를 치료하기 위한 이의 용도
US20050025718A1 (en) 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ATE526967T1 (de) 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PL1713471T3 (pl) 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
ES2309705T3 (es) 2004-02-06 2008-12-16 MEDA PHARMA GMBH &amp; CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
SI1713473T1 (sl) 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
US7712077B2 (en) * 2004-02-27 2010-05-04 International Business Machines Corporation Method and system for instantiating components conforming to the “COM” specification in custom contexts
ES2239546B1 (es) 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
DE102004016179A1 (de) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
PT1765404E (pt) 2004-05-31 2009-03-31 Almirall Lab Combinações compreendendo agentes antimuscarínicos e agonistas beta-adrenérgicos
CA2603433A1 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
WO2008102128A2 (en) 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
HRP20110556T1 (hr) 2007-02-21 2011-09-30 Almirall Novi postupci
WO2009004502A1 (en) 2007-07-03 2009-01-08 Nxp B.V. Calibration of an amr sensor
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
SMT202200303T1 (it) 2012-12-17 2022-09-14 Almirall Sa Aclidinio per l’uso nell’aumento dell’attività fisica nella vita quotidiana in un paziente con broncopneumopatia cronica ostruttiva

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302699A2 (en) * 1987-08-03 1989-02-08 Walton S.A. Improvements relating to n-substituted benzamides
EP0424021A1 (en) * 1989-10-19 1991-04-24 Pfizer Limited Antimuscarinic bronchodilators

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
ES2206021A1 (es) * 2002-04-16 2004-05-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2298049A1 (es) * 2006-07-21 2008-05-01 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Also Published As

Publication number Publication date
JP2005350476A (ja) 2005-12-22
DE60001840D1 (de) 2003-04-30
PL357160A1 (en) 2004-07-12
EE200200017A (et) 2003-04-15
US20080221155A1 (en) 2008-09-11
NO329484B1 (no) 2010-10-25
TR200200768T2 (tr) 2002-07-22
CY2013001I2 (el) 2015-10-07
US20170319557A1 (en) 2017-11-09
CA2381165F (en) 2001-01-18
BG106301A (en) 2002-08-30
IL147533A0 (en) 2002-08-14
US8802699B2 (en) 2014-08-12
US8129405B2 (en) 2012-03-06
MY126959A (en) 2006-11-30
USRE46417E1 (en) 2017-05-30
FR13C0001I1 (es) 2013-01-03
SI1200431T1 (en) 2003-10-31
US20120122826A1 (en) 2012-05-17
US7897617B2 (en) 2011-03-01
US7109210B2 (en) 2006-09-19
CA2381165C (en) 2009-10-27
AU6433000A (en) 2001-01-30
UY33494A (es) 2013-04-05
EP1200431B1 (en) 2003-03-26
HUP0202100A2 (en) 2002-10-28
JP4951217B2 (ja) 2012-06-13
JP2003504368A (ja) 2003-02-04
LU92132I2 (fr) 2013-03-18
US10588895B2 (en) 2020-03-17
CN1373760A (zh) 2002-10-09
CN1272334C (zh) 2006-08-30
US20150246026A1 (en) 2015-09-03
EE04915B1 (et) 2007-10-15
US10034867B2 (en) 2018-07-31
WO2001004118A2 (en) 2001-01-18
EG24066A (en) 2008-05-08
KR20070009744A (ko) 2007-01-18
US20050209272A1 (en) 2005-09-22
PL204024B1 (pl) 2009-12-31
RU2264401C3 (ru) 2018-06-01
PT1200431E (pt) 2003-07-31
US20110118223A1 (en) 2011-05-19
ES2193098T7 (es) 2012-12-13
ES2165768B1 (es) 2003-04-01
KR100854315B1 (ko) 2008-08-26
SK287480B6 (sk) 2010-11-08
US9056100B2 (en) 2015-06-16
US20160296503A1 (en) 2016-10-13
CZ2002121A3 (cs) 2002-11-13
US20040132768A1 (en) 2004-07-08
UY26244A1 (es) 2000-12-29
US20140303126A1 (en) 2014-10-09
US7358260B2 (en) 2008-04-15
NO20020180D0 (no) 2002-01-14
RU2306312C2 (ru) 2007-09-20
US20130310353A1 (en) 2013-11-21
DK1200431T5 (da) 2005-01-31
KR100773844B1 (ko) 2007-11-06
UA73509C2 (uk) 2005-08-15
US20100234333A1 (en) 2010-09-16
HU228594B1 (en) 2013-04-29
US7078412B2 (en) 2006-07-18
BRPI0012434B8 (pt) 2021-05-25
US20190183867A1 (en) 2019-06-20
ZA200200232B (en) 2003-04-10
HUP0202100A3 (en) 2003-09-29
SK432002A3 (en) 2003-04-01
US20030055080A1 (en) 2003-03-20
PE20010397A1 (es) 2001-04-11
EE04915B3 (et) 2016-07-15
US8513279B2 (en) 2013-08-20
EP1200431B3 (en) 2015-06-24
AU779881B2 (en) 2005-02-17
CZ304292B6 (cs) 2014-02-19
ES2193098T3 (es) 2003-11-01
US7196098B2 (en) 2007-03-27
DE60001840T2 (de) 2003-12-11
US6750226B2 (en) 2004-06-15
AR029760A1 (es) 2003-07-16
DE60001840T3 (de) 2015-10-08
BR0012434A (pt) 2002-04-02
US9687478B2 (en) 2017-06-27
NO2013002I1 (no) 2013-02-11
KR100854321B1 (ko) 2008-08-26
RU2005121162A (ru) 2007-01-20
US20070099953A1 (en) 2007-05-03
CO5200759A1 (es) 2002-09-27
FR13C0001I2 (fr) 2013-11-01
AU2005202144A1 (en) 2005-06-09
CY2013001I1 (el) 2015-10-07
CA2381165A1 (en) 2001-01-18
DE60001840T4 (de) 2015-11-26
US9333195B2 (en) 2016-05-10
DK1200431T6 (en) 2015-09-28
NO2013002I2 (no) 2013-09-09
TWI284644B (en) 2007-08-01
US7750023B2 (en) 2010-07-06
CN100451018C (zh) 2009-01-14
EP1200431A2 (en) 2002-05-02
BG65565B1 (bg) 2008-12-30
WO2001004118A3 (en) 2001-07-19
HK1042487B (en) 2003-07-18
KR20070007396A (ko) 2007-01-15
NO20020180L (no) 2002-03-13
KR20020021155A (ko) 2002-03-18
CN1824664A (zh) 2006-08-30
AU2005202144B2 (en) 2007-06-14
US20060106056A1 (en) 2006-05-18
BE2013C001I2 (es) 2019-05-21
JP4030040B2 (ja) 2008-01-09
DK1200431T3 (da) 2003-07-21
ATE235492T1 (de) 2003-04-15
NO329484B3 (no) 2013-04-29
RU2264401C2 (ru) 2005-11-20
BRPI0012434B1 (pt) 2016-03-22

Similar Documents

Publication Publication Date Title
ES2165768A1 (es) Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
MY136067A (en) Novel quinuclidine derivatives and medicinal compositions containing the same
IL142359A0 (en) Quinazoline derivatives
WO2007018738A3 (en) Fused bicycloheterocycle substituted quinuclidine derivatives
CA2160444A1 (en) Aroyl-piperdine derivatives
CA2205757A1 (en) Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
WO2001058869B1 (en) Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
CA2327253A1 (en) Sulfonamide-containing indole compounds
IE45744L (en) 5-ALKOXYIMIDAZO [1,2-a]-QUINOLINE-2-CARBOXYLIC ACIDS
SI9520081B (sl) Uporaba tiazolnih in tiadiazolnih spojin
CA2083639A1 (en) Substituted phenyl phenol leukotriene antagonists
ZA200203305B (en) Benzothiadiazine derivatives, preparation method and pharmaceutical compositions containing same.
FI960571A0 (fi) Kolekystokiniini- ja gastriiniantagonisteina käyttökelpoisia bisyklo(2.2.2)oktaanijohdannaisia
KR900018100A (ko) N-(5,6,7,8-테트라히드로피리도(2,3,-d)피리미딘-6-일-알카노일)-글루탐산 유도체 및 그의 제조방법
GB9306899D0 (en) Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
WO2005053702A3 (en) Anti-inflammatory agents
SE8205867L (sv) Nya 4-fenyl-4-oxo-2-butensyraderivat, deras salter, framstellning derav, anvendning derav som lekemedel och kompositioner innehallande dem
BR9912638A (pt) Antagonistas receptores de vitronectina
BR0212839A (pt) Derivados de alquilaminopiridazinona substituìdos, processo para a preparação destes e composição farmacêutica contendo os mesmos
PT90302A (pt) Processo para a preparacao de derivados de lactamas hetero-tetraciclicas
AU1597092A (en) 2-piperazinylbenzimidazole derivatives and processes for the preparation thereof
IL67564A (en) 7-heteroaryl-(1,2)-fused 1,4-benzodiazepine compounds,their preparation and pharmaceutical compositions containing them
IL115085A0 (en) Bicyclic carboxamide derivatives their preparation and pharmaceutical compositions containing them
ES487971A1 (es) Procedimiento para la preparacion de nuevos derivados de p-cloroacetofenona oxima con actividad analgesica

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020316

Kind code of ref document: A1

Effective date: 20020316

FG2A Definitive protection

Ref document number: 2165768B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100315